Drugs / IVX037
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05427487 | Feb 2023 → Jun 2028 expected | colorectal cancer, gastric cancer, ovarian cancer | ImmVirx Pty Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IVX037 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05427487 ↗ |
| Modality | Other / unclassified | “Bioselected oncolytic RNA virus” NCT05427487 ↗ |
| Route | Other | “IVX037 administered intratumorally” NCT05427487 ↗ |